Clinical trialNCT06975111RecruitingPhase 2/PHASE3Interventional

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

SponsorUniversity of Colorado, DenverEnrollment200CardiovascularMenopauseMenopause Hot FlashesMenopause Related Conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Nanette Santoro, MD
University of Colorado, Denver
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Colorado-School of Medicine
Aurora, Colorado, United States
Recruiting
University of North Carolina, School of Medicine
Chapel Hill, North Carolina, United States
Genevieve Neal-Perry, MD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
Samar El Khoudary, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anti-hypertensivesFezolinetant →Hormonal therapyLipid Lowering MedicationMetformin →Semaglutide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Mar 2026
Primary completion: 31 Oct 2029
Completion: 1 Oct 2030
Last update posted: 21 Jul 2026
Registered enrollment: 200
Registry id: NCT06975111

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.